Q3 2024 Earnings Estimate for Cryoport, Inc. Issued By Leerink Partnrs (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRX) – Stock analysts at Leerink Partnrs upped their Q3 2024 earnings estimates for Cryoport in a report issued on Tuesday, August 6th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Cryoport’s current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Cryoport’s Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.78) EPS and FY2026 earnings at ($0.67) EPS.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($1.25). Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. The firm had revenue of $57.60 million for the quarter, compared to analysts’ expectations of $57.65 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year.

Several other research analysts have also recently weighed in on CYRX. B. Riley upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and cut their price target for the stock from $19.00 to $15.00 in a report on Wednesday, July 31st. Needham & Company LLC lowered their price objective on shares of Cryoport from $18.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday. UBS Group lowered their price objective on shares of Cryoport from $17.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Jefferies Financial Group lowered shares of Cryoport from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $20.00 to $8.00 in a research report on Wednesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.33.

Cryoport Stock Up 0.9 %

Cryoport stock opened at $8.23 on Friday. Cryoport has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The stock has a market cap of $405.39 million, a PE ratio of -3.33 and a beta of 1.59. The firm’s 50-day simple moving average is $8.47 and its 200 day simple moving average is $13.13. The company has a debt-to-equity ratio of 0.86, a quick ratio of 10.22 and a current ratio of 10.73.

Insider Activity

In other news, Director Richard J. Berman sold 8,105 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total value of $108,688.05. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at $1,341,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Edward J. Zecchini sold 3,443 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total transaction of $46,032.91. Following the completion of the transaction, the insider now directly owns 60,051 shares in the company, valued at $802,881.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard J. Berman sold 8,105 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total value of $108,688.05. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $1,341,000. The disclosure for this sale can be found here. Insiders have sold a total of 15,715 shares of company stock valued at $188,224 over the last quarter. Company insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Comerica Bank lifted its position in Cryoport by 73.0% during the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock valued at $62,000 after purchasing an additional 1,469 shares during the last quarter. Natixis Investment Managers International grew its stake in Cryoport by 61.5% in the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after buying an additional 1,727 shares in the last quarter. Lazard Asset Management LLC grew its stake in Cryoport by 294.3% in the 1st quarter. Lazard Asset Management LLC now owns 5,378 shares of the company’s stock worth $95,000 after buying an additional 4,014 shares in the last quarter. Quest Partners LLC grew its stake in Cryoport by 1,083,000.0% in the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after buying an additional 10,830 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in Cryoport by 5.4% in the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock worth $212,000 after buying an additional 696 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.